Trial reportIntensive care medicine2022
Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia.
Trial report in Intensive care medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 14 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 14 syntheses or guidelines pooled it.
- Low-dose corticosteroids in severe pulmonary infection: a meta-analysis of randomised controlled trials.BMJ open respiratory research · 2026Pooled it
- Efficacy of higher-dose versus lower-dose corticosteroids in community-acquired pneumonia: a systematic review and network meta-analysis.Critical care (London, England) · 2026Pooled it
- Efficacy and safety of corticosteroids in critically ill patients: a systematic review and meta-analysis.BMC anesthesiology · 2025Pooled it
- Corticosteroids for treating sepsis in children and adults.The Cochrane database of systematic reviews · 2025Pooled it
- Corticosteroids for adult patients hospitalised with non-viral community-acquired pneumonia: a systematic review and meta-analysis.Intensive care medicine · 2025Pooled it
- Efficacy and safety of glucocorticoids therapy of severe community-acquired pneumonia in older adults: a systematic review and meta-analysis.BMC geriatrics · 2025Pooled it
- Glucocorticoids can reduce mortality in patients with severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials.European journal of medical research · 2025Pooled it
- Impact of different corticosteroids on severe community-acquired pneumonia: a systematic review and meta-analysis.BMJ open respiratory research · 2024Pooled it
- Association between various types of corticosteroids and mortality for severe community-acquired pneumonia in adults: a systematic review and network meta-analysis.Frontiers in pharmacology · 2024Pooled it
- The effect and safety of corticosteroid treatment for severe community-acquired pneumonia: a meta-analysis of randomized controlled trials.Frontiers in medicine · 2024Pooled it
- Major Publications in the Critical Care Pharmacotherapy Literature: 2022.Critical care explorations · 2023Pooled it
- Corticosteroids in Community-Acquired Bacterial Pneumonia: a Systematic Review, Pairwise and Dose-Response Meta-Analysis.Journal of general internal medicine · 2023Pooled it
- Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials.Critical care (London, England) · 2023Pooled it
- Pooled it
- A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.The New England journal of medicine · 2025Trial
- Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial.Intensive care medicine · 2025Trial
- Ventilator-Associated Pneumonia: The Role of Kidney-Lung Crosstalk and Renal Replacement Therapy, a Narrative Review.Journal of clinical medicine · 2026Review
- Ventilatory Parameters and Adjunctive Therapies Associated with ICU Mortality in Severe Pneumonia: A Large Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Critical care delirium: prevention, identification and management: a narrative review.Anaesthesia · 2026Review
- The Impact of Black Race on Pneumonia Severity Scoring Systems.CHEST pulmonary · 2026Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
23 authors.
Funding
Abstract
purposeSevere community-acquired pneumonia (CAP) requiring intensive care unit admission is associated with significant acute and long-term morbidity and mortality. We hypothesized that downregulation of systemic and pulmonary inflammation with prolonged low-dose methylprednisolone treatment would accelerate pneumonia resolution and improve clinical outcomes.
methodsThis double-blind, randomized, placebo-controlled clinical trial recruited adult patients within 72-96 h of hospital presentation. Patients were randomized in 1:1 ratio; an intravenous 40 mg loading bolus was followed by 40 mg/day through day 7 and progressive tapering during the 20-day treatment course. Randomization was stratified by site and need for mechanical ventilation (MV) at the time of randomization. Outcomes included a primary endpoint of 60-day all-cause mortality and secondary endpoints of morbidity and mortality up to 1 year of follow-up.
resultsBetween January 2012 and April 2016, 586 patients from 42 Veterans Affairs Medical Centers were randomized, short of the 1420 target sample size because of low recruitment. 584 patients were included in the analysis. There was no significant difference in 60-day mortality between the methylprednisolone and placebo arms (16% vs. 18%; adjusted odds ratio 0.90, 95% CI 0.57-1.40). There were no significant differences in secondary outcomes or complications.
conclusionsIn patients with severe CAP, prolonged low-dose methylprednisolone treatment did not significantly reduce 60-day mortality. Treatment was not associated with increased complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.